NovaBay Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference
09/23/2022 - 06:50 AM
EMERYVILLE, Calif. --(BUSINESS WIRE)--
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that management will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29 at 9:00 a.m. Eastern time (6:00 a.m. Pacific time ). The conference is being held at the Sofitel Hotel New York . A webcast of the presentation will be available on the Events page of the company website.
About NovaBay Pharmaceuticals, Inc :
NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that develops and sells scientifically created and clinically proven consumer products for the eyecare and skincare markets. Avenova® is the most prescribed antimicrobial lid and lash spray and DERMAdoctor® is a premium skincare brand offering more than 30 dermatologist-developed skincare products sold through traditional domestic retailers, digital beauty channels and international distributors.
Socialize and Stay Informed on NovaBay ’ s Progress
Facebook
Twitter
LinkedIn
Website
Avenova Purchasing Information
sales@avenova.com
Avenova.com
DERMAdoctor Purchasing Information
service@dermadoctor.com
DERMAdoctor.com
View source version on businesswire.com : https://www.businesswire.com/news/home/20220923005086/en/
NovaBay Contact
Justin Hall
jhall@novabay.com
Investor Contact
Jody Cain
jcain@lhai.com
Source: NovaBay Pharmaceuticals, Inc.
Novabay Pharmaceuticals Inc
NBY Rankings
N/A Ranked by Stock Gains
NBY Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Emeryville
About NBY
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
